Sermorelin works by stimulating the pituitary gland to release more of the bodys own growth hormone
The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
was briefly on WADA watch list TB-500 Not approved Prohibited Research use only Thymosin Alpha-1 Not approved in US Permitted Approved in some countries (Italy, China) Ipamorelin Not approved Prohibited Research use only Key point: None of these compounds are FDA-approved for human therapeutic use in the United States
Required documentation includes recent testosterone lab results, symptom questionnaires, physical examination findings, and treatment rationale
